GATC Biotech first in Europe to use PacBio RS gene sequencer
11 Oct 2010
German gene sequencing service provider GATC Biotech has
announced that it has agreed to purchase the PacBio RS platform, a
single molecule, real-time (SMRT) gene sequencing technology.
The new PacBio RS will be the fifth sequencing technology for the
company. The system is planned for installation in early 2011.
GATC Biotech plans to use the new platform for resolving
structural variations, for example in human cancer genomes, and for
the detection and confirmation of rare SNPs. In addition, the future
application to enable direct sequencing of methylated bases will
make the system attractive for regulatory studies, for example for
the pharmaceutical or diagnostics industry.
“Pacific Biosciences has chosen GATC Biotech to be our first
European service provider because the company is well experienced in
applying major sequencing technologies in a broad spectrum of
projects and in gearing up new sequencing technologies quickly for
lab routines,” commented Terry Pizzie, Vice President, Europe for
“We are looking forward to offering our customers PacBio’s
third-generation sequencing platform and are confident that we will
be able to offer the SMRT technology to our customers within a short
period of time after successful installation,” adds Thomas Pohl,
Chief Technology Officer of GATC Biotech.